Ekins Sean, Berbaum Jennifer, Harrison Richard K
Concurrent Pharmaceuticals Inc, Fort Washington, PA 19034, USA.
Drug Metab Dispos. 2003 Sep;31(9):1077-80. doi: 10.1124/dmd.31.9.1077.
CYP2D6 and CYP3A4 represent two particularly important members of the cytochrome p450 enzyme family due to their involvement in the metabolism of many commercially available drugs. Avoiding potent inhibitory interactions with both of these enzymes is highly desirable in early drug discovery, long before entering clinical trials. Computational prediction of this liability as early as possible is desired. Using a commercially available data set of over 1750 molecules to train computer models that were generated with commercially available software enabled predictions of inhibition for CYP2D6 and CYP3A4, which were compared with empirical data. The results suggest that using a recursive partitioning (tree) technique with augmented atom descriptors enables a statistically significant rank ordering of test-set molecules (Spearman's rho of 0.61 and 0.48 for CYP2D6 and CYP3A4, respectively), which represents an increased rate of identifying the best compounds when compared with the random rate. This approach represents a valuable computational filter in early drug discovery to identify compounds that may have p450 inhibition liabilities prior to molecule synthesis. Such computational filters offer a new approach in which lead optimization in silico can occur with virtual molecules simultaneously tested against multiple enzymes implicated in drug-drug interactions, with a resultant cost savings from a decreased level of molecule synthesis and in vitro screening.
细胞色素P450酶家族中,CYP2D6和CYP3A4是两个特别重要的成员,因为它们参与了许多市售药物的代谢。早在进入临床试验之前的早期药物发现阶段,就非常希望避免与这两种酶发生强效抑制性相互作用。因此需要尽早对这种风险进行计算预测。利用一个包含超过1750个分子的商业数据集来训练通过商业软件生成的计算机模型,从而实现对CYP2D6和CYP3A4抑制作用的预测,并将其与实验数据进行比较。结果表明,使用带有增强原子描述符的递归划分(树)技术能够对测试集分子进行具有统计学意义的排序(CYP2D6和CYP3A4的斯皮尔曼等级相关系数分别为0.61和0.48),与随机排序相比,这代表着识别最佳化合物的成功率有所提高。这种方法在早期药物发现中是一种有价值的计算筛选工具,可在分子合成之前识别可能具有P450抑制风险的化合物。此类计算筛选工具提供了一种新方法,即可以对虚拟分子进行计算机辅助先导优化,同时针对涉及药物相互作用的多种酶进行测试,从而通过减少分子合成和体外筛选的水平实现成本节约。